Xospata leads latest CHMP recommendations
The committee has recommended seven medicines for approval at its September 2019 meeting.
Read More
Tag: Marketing Authorisation
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More
AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Read More
Darolutamide submitted for EU approval
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Read More
Lusutrombopag gets EU green light for liver disease
Marketing authorisation in the EU has been granted for Shionogi’s lusutrombopag in severe thrombocytopenia.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
